These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 11904963

  • 1. [Humanized respiratory syncytial virus monoclonal antibody].
    Tsutsumi H.
    Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
    [Abstract] [Full Text] [Related]

  • 2. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 3. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 4. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR, Hoopes JM, Hemming VG.
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [Abstract] [Full Text] [Related]

  • 5. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [Abstract] [Full Text] [Related]

  • 6. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B, Müller W.
    Klin Padiatr; 1999 Feb; 211(6):450-5. PubMed ID: 10592925
    [Abstract] [Full Text] [Related]

  • 7. New strategies for control of respiratory syncytial virus infection.
    Nokes JD, Cane PA.
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR.
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
    Cardenas S, Auais A, Piedimonte G.
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
    Nuijten M, Lebmeier M, Wittenberg W.
    J Med Econ; 2009 Oct; 12(4):291-300. PubMed ID: 19811111
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.